Nelson K Y Wong
Overview
Explore the profile of Nelson K Y Wong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
86
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang S, Xue H, Wong N, Doerksen T, Ban F, Anderson S, et al.
Mol Cancer Ther
. 2025 Mar;
PMID: 40062378
Nucleobase analogue (NBA) drugs, such as 5-fluorouracil (5-FU), are effective chemotherapeutics, but their clinical use is limited by severe side effects. Compelling evidence suggests that the use of S-methyl-5'-thioadenosine (MTA)...
2.
Kang N, Xue H, Wong N, Lin Y, Classen A, Wu R, et al.
Mol Cancer Res
. 2025 Jan;
PMID: 39776163
Prostate cancer (PCa) is mainly managed with androgen deprivation therapy (ADT), but this often leads to a dormant state and subsequent relapse as lethal castration-resistant prostate cancer (CRPC). Using our...
3.
Dhillon G, Llaurado-Fernandez M, Tessier-Cloutier B, Sy K, Bassiouny D, Han G, et al.
Front Oncol
. 2024 Sep;
14:1408196.
PMID: 39220645
Objectives: Ovarian carcinosarcoma (OCS) is a rare and lethal type of ovarian cancer. Despite its incredibly poor prognosis, it has received little research attention. In this study, we aim to...
4.
Kumar P, Smith D, Key J, Dong H, Ganapathysamy A, Maranda V, et al.
Gynecol Oncol
. 2024 Jul;
188:162-168.
PMID: 38970843
Objective: Dedifferentiated endometrial carcinoma (DDEC) characterized by SWItch/Sucrose Non-Fermentable (SWI/SNF) complex inactivation is a highly aggressive type of endometrial cancer without effective systemic therapy options. Its uncommon nature and aggressive...
5.
Mao Y, Lin Y, Wong N, Volik S, Sar F, Collins C, et al.
Bioinformatics
. 2024 Feb;
40(2).
PMID: 38390963
Motivation: A patient's disease phenotype can be driven and determined by specific groups of cells whose marker genes are either unknown or can only be detected at late-stage using conventional...
6.
Wong N, Fernandez M, Kommoss F, Kumar P, Kim H, Liu J, et al.
Gynecol Oncol
. 2023 Aug;
176:162-172.
PMID: 37556934
Objective: Dedifferentiated endometrial cancer (DDEC) is an uncommon and clinically highly aggressive subtype of endometrial cancer characterized by genomic inactivation of SWItch/Sucrose Non-Fermentable (SWI/SNF) complex protein. It responds poorly to...
7.
Fernandez M, Hijmans E, Gennissen A, Wong N, Li S, Wisman G, et al.
Mol Cancer Ther
. 2022 Oct;
21(12):1862-1874.
PMID: 36198031
Low-grade serous ovarian cancer (LGSOC) is a rare subtype of epithelial ovarian cancer with high fatality rates in advanced stages due to its chemoresistant properties. LGSOC is characterized by activation...
8.
Wong N, Dong X, Lin Y, Xue H, Wu R, Lin D, et al.
Cells
. 2022 May;
11(9).
PMID: 35563856
Androgen deprivation therapy (ADT) is the standard therapy for men with advanced prostate cancer (PCa). PCa often responds to ADT and enters a dormancy period, which can be recognized clinically...
9.
Modeling Androgen Deprivation Therapy-Induced Prostate Cancer Dormancy and Its Clinical Implications
Dong X, Xue H, Mo F, Lin Y, Lin D, Wong N, et al.
Mol Cancer Res
. 2022 Jan;
20(5):782-793.
PMID: 35082166
Implications: We have established highly clinically relevant PDXs of ADT-induced dormant prostate cancer and identified two dormancy subtypes, leading to the development of a novel predicative gene signature that allows...
10.
Shrestha R, Fernandez M, Dawson A, Hoenisch J, Volik S, Lin Y, et al.
Cancer Res
. 2021 Jan;
81(7):1681-1694.
PMID: 33441310
Low-grade serous ovarian carcinoma (LGSOC) is a rare tumor subtype with high case fatality rates in patients with metastatic disease. There is a pressing need to develop effective treatments using...